BUSINESS● LOWOct 4 · Oct 4, 2026, 10:41 PM
CSL strikes $1.6B deal with Alentis for experimental kidney, liver drug
Seeking Alpha Tech · global
CSL has finalized a $1.6 billion agreement with Alentis for the development of an experimental drug targeting kidney and liver conditions.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS32m agoHong Kong’s primary residential market sees wave of launches, successful salesSouth China Morning PostBUSINESS57m agoRokid launches ‘no man’s land’ retail experience with Hong Kong flagship store openingSouth China Morning Post